Veletri is owned by Actelion.
Veletri contains Epoprostenol Sodium.
Veletri has a total of 2 drug patents out of which 0 drug patents have expired.
Veletri was authorised for market use on 27 June, 2008.
Veletri is available in injectable;injection dosage forms.
The generics of Veletri are possible to be released after 15 March, 2027.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8598227||ACTELION||Epoprostenol formulation and method of making thereof|| |
(3 years from now)
|US8318802||ACTELION||Epoprostenol formulation and method of making thereof|| |
(4 years from now)
Market Authorisation Date: 27 June, 2008
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic